NCT00775203已完成3 期
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 412
- 主要终点
- Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline
研究概览
简要总结
The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).
详细描述
This two-arm, multicentre, randomized, placebo-controlled, double-blind, parallel-design study consisted of a baseline phase (screening and wash-out) and a double-blind randomized phase (randomization to Trazodone Contramid® OAD or placebo). The total study duration including wash-out of prohibited medications was approximately 11 weeks; the total duration of the randomized phase was 8 weeks (titration: 2 weeks + treatment: 6 weeks).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females.
- •Aged 18 years or older.
- •Fulfills Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for Unipolar Major Depressive Disorder (MDD) (Axis I) as confirmed by the Mini-International Neuropsychiatric Interview (MINI).
- •The primary DSM-IV Axis I diagnosis should be MDD (296.22, 296.23, 296.32, 296.33); any subject meeting criteria for another, non excluded Axis I disorder, must demonstrate MDD as the primary disorder.
- •The current episode of MDD should have lasted for a minimum of 1 month, whether the patient has been diagnosed with one single or recurrent episodes.
- •Presence of dysphoria for most days over the past four weeks.
- •Montgomery-Åsberg Depression Rating Scale (MADRS) total score of at least 26 at screening and baseline.
- •Oral and written language comprehension at a level sufficient to comply with the protocol and to complete study-related materials.
- •Sign and date a written Informed Consent Form (ICF) approved by a Research Ethic Board (REB) which has also been signed and dated by the Investigator prior to study participation.
排除标准
- •DSM-IV Major Depressive Disorder Specifiers: [a] With Catatonic Features; [b] With Postpartum Onset; [c] With Seasonal Pattern;
- •Presence of any of the following DSM-IV Axis I disorders: generalized anxiety disorder, panic disorder, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, eating disorder, bipolar disorder, alcohol/substance abuse or dependence (caffeine and nicotine allowed), any psychotic disorder.
- •Depression secondary to stroke, cancer or other severe medical illnesses.
- •Positive urine drug screen at screening visit.
- •History or present condition of any DSM-IV Axis II disorder.
- •History of treatment refractory major depressive episodes defined as incomplete or no therapeutic response to two prior courses of at least one month of conventional antidepressant drug treatment in adequate dosages.
- •Currently in psychotherapy (at least one session in the past month with a plan for continuing) with a licensed/registered/certified mental health provider, marriage counselor, or family therapist.
- •Meet criteria for high suicide risk on the MINI suicide scale, or in the opinion of the investigator is inappropriate for the trial due to clinically significant suicidal or homicidal potential.
- •Require hospitalization for treatment of the current episode of depression.
- •Uncorrected hypo- or hyperthyroidism.
- •A history of seizures other than pediatric febrile seizure.
- •A history of cardiac arrythmias requiring therapy.
- •A history of myocardial infarction within 1 year before screening.
- •Clinically significant abnormal findings of Electrocardiography (ECG), laboratory parameters.
- •Unwilling to discontinue use of any antidepressants, including herbal remedies, for a minimum of 5 drug half-lives prior to screening.
- •Unwilling to discontinue use of prohibited medications for a minimum of 5 drug half-lives prior to screening.
- •Treatment within the last 3 weeks with Monoamine Oxidase (MAO) inhibitors.
- •Use of the following concomitant treatment during the study:
- •medications causing QT prolongation (e.g. amiodarone, droperidol, erythromycin).
- •medications causing PR prolongation (e.g. digoxin).
- •Anti -psychotics (e.g. haloperidol).
- •protease inhibitors such as ritonavir and indinavir.
- •Hormonal treatment (e.g. estrogen, oral contraceptives) which has started within 3 months of study entry.
- •Treatment with another investigational agent within the last 30 days.
- •Known and documented allergy to trazodone or any structurally similar drugs.
- •Previous failure of treatment with trazodone, or previous discontinuation of treatment with trazodone due to Adverse Events.
- •Bowel disease causing malabsorption.
- •Serious, unstable illnesses during the 3 months before screening including but not limited to: hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic or hematological disease.
- •Pregnant or lactating, or is of childbearing potential and not willing to use an approved method of contraception.
- •Significant liver disease, defined as active hepatitis or elevated liver enzymes >3 times the upper boundary of the normal range.
- •Significant renal disease, defined as Blood Urea Nitrogen (BUN) and/or creatinine >3 times the upper boundary of the normal range clearance.
- •Any other condition that, in the opinion of the investigators, would adversely affect the patient's ability to complete the study or its measures.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Trazodone Contramid Once A Day (OAD)
Experimental
干预措施: Trazodone Hydrochloride (HCl) Extended-Release Tablets (Drug)
结局指标
主要结局
Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline
时间窗: Baseline to Week 8
The Hamilton Depression Rating Scale 17 items \[HAMD-17\] is a 17-item scale that evaluates depressed mood, vegetative and cognitive symptoms of depression, and co-morbid anxiety symptoms. The 17 items are rated on either a 5-point (0-4) or a 3-point (0-2) scale. In general, the 5 point scale items use a rating of 0=absent; 1=doubtful to mild; 2=mild to moderate; 3=moderate to severe; 4=very severe. The 3-point scale items use a rating of 0=absent; 1=probable or mild; 2=definite. The total HAMD-17score ranges from 0 (not ill) to 52 (severely ill).
次要结局
- HAMD-17 Responders at Each Visit(Weeks 1, 2, 3, 4, 6, 8)
- HAMD-17 Remitters at Each Visit(Weeks 1, 2, 3, 4, 6, 8)
- Change in HAMD-17 Depressed Mood Item (Item 1) Score From Baseline to Each Visit(Baseline to Weeks 1, 2, 3, 4, 6, 8)
- Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline(Baseline to Week 8)
- Change From Baseline in Clinical Global Impression of Severity (CGI-S) to Each Visit(Baseline to Weeks 1, 2, 3, 4, 6, 8)
- Clinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit(Week 8)
- Patient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit(Week 8)
- Clinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit(Week 8)
- Patient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit(Week 8)
- Overall Quality of Sleep at Each Visit(Weeks 1, 2, 3, 4, 6, 8)
- Trouble Falling Asleep at Each Visit(Weeks 1, 2, 3, 4, 6, 8)
- Awakening During the Night at Each Visit(Weeks 1, 2, 3, 4, 6, 8)
- Discontinuation Due to Lack of Efficacy(Baseline to Week 8)
研究者
相似试验
已完成
2 期
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of DepressionDepressionNCT01524497Lee's Pharmaceutical Limited382
已完成
4 期
Vilazodone for the Treatment of Posttraumatic Stress DisorderPTSDDepressionNCT01715519Southern California Institute for Research and Education59
已完成
3 期
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive DisorderMajor Depressive DisorderNCT01878292Forest Laboratories529
已完成
3 期
Trazodone Once a Day in Major Depression DisorderMajor Depressive DisorderNCT02086929Aziende Chimiche Riunite Angelini Francesco S.p.A364
已完成
3 期
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative ColitisUlcerative ColitisNCT02065557AbbVie101